The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults ...

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis ...

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, ...

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.